中藥是一個(gè)復(fù)雜的巨系統(tǒng)，其藥效是其中多種化學(xué)成分相互作用所產(chǎn)生的綜合效果。中藥藥動(dòng)學(xué)研究經(jīng)歷了從“單成分、單靶點(diǎn)”到“多成分、多靶點(diǎn)”的轉(zhuǎn)變，相應(yīng)的藥動(dòng)學(xué)評(píng)價(jià)模式也經(jīng)歷了相似的發(fā)展過(guò)程，從最初針對(duì)單體成分的藥動(dòng)學(xué)研究，到以單成分研究單味中藥及復(fù)方的藥動(dòng)學(xué)，再到多組分整合藥動(dòng)學(xué)，以及之后的以藥動(dòng)學(xué)–藥效學(xué)結(jié)合模式評(píng)價(jià)復(fù)方藥動(dòng)學(xué)。對(duì)以上中藥藥動(dòng)學(xué)評(píng)價(jià)模式的發(fā)展進(jìn)行了初步探討。

Chinese materia medica (CMM) is a complicated macrosystem, and the efficacy is synthetic by variety of chemical composition. The pharmacokinetic study of CMM transformed from “single component, single targets” to “multiple components, multiple targets”, and its evaluation mode transformed in a similar process: pharmacokinetic study aimed at monomer composition, pharmacokinetic study of single Chinese herb or compound prescription through single component, integrated pharmacokinetics of multicomponent, and uses of pharmacokinetics/pharmacodynamics binding mode to evaluate the pharmacokinetics of CMM, and this development process was discussed primarily in this article.